China (Mainland)
Premiumsupplier
Anastrozole Manufacturer For Anti-breast Cancer CAS NO.120511-73-1
- Min.Order: 10 Gram
- Payment Terms: T/T,MoneyGram
- Product Details
Keywords
- 99% Anastrozole
- Anastrozole Manufacturer
- API Manufacturer
Quick Details
- ProName: Anastrozole Manufacturer For Anti-brea...
- CasNo: 120511-73-1
- Molecular Formula: C17H19N5
- Appearance: White Powder
- Application: It Can Be Used As Pharmaceutical Inte...
- DeliveryTime: 2-4 days after confirming your payment...
- PackAge: 100g/ bag, 2 kg/ bag, 25kg/ carton or ...
- Port: Wuhan
- ProductionCapacity: 10000 Metric Ton/Month
- Purity: 99%
- Storage: Store in sealed containers at cool & d...
- Transportation: By DHL, TNT, FedEx, HKEMS, UPS, Etc
- LimitNum: 10 Gram
Superiority
Advantages:
Hubei XinRunde Chemical Co., Ltd is a renowned pharmaceutical manufacturer. We can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. Never stop striving to offer our best service is our philosophy. We have Flexible and Untraceable payment terms. As a leading manufacture, our products have been exported to Germany, Norway, Poland, Finland, Spain, UK, France, Russia, USA, Brazil, Mexico, Australia, Japan, Korea, Thailand, Indonesia, Uruguay and many other countries.
1. Quality.Every batch of steroid powders have tobetested by our QC(quality control) before they are allowed to sell.
2. Delivery We have stock, so we can delivery quickly at the very day when receive the payment. Within 24 hours after receiving the payment Lead time 4 or 7 days.
3. Discreet package Safelyand Professionally Disguised Package Guaranteed. For your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate.
4. Warm after-sale service Any of your question would be solved for the first as soon as possible.
Details
| Anastrozole Basic information |
| Product Name: | Anastrozole |
| Synonyms: | ICI-D-1033;ARIMIDEX;1-[3,5-DI-(1-METHYL-1-CYANO)-ETHYL]-BENZYL-1,2,4-TRIAZOLE;ANASTRAZOLE;ANASTROZOLE;tetramethyl-5-(1h-1,2,4-triazol-1ylmethyl) 1,3-benzenediacetionitrile;ZD-1033;1,3-benzenediacetonitrile,alpha,alpha,alpha’,alpha’-tetramethyl-5-(1h-1,2,4-t |
| CAS: | 120511-73-1 |
| MF: | C17H19N5 |
| MW: | 293.37 |
| EINECS: | |
| Product Categories: | Active Pharmaceutical Ingredients;Antineoplastic;All Inhibitors;anti-neoplastic;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Anastrozole;API |
| Mol File: | 120511-73-1.mol |
|
|
|
| Anastrozole Chemical Properties |
| Melting point | 81-82°C |
| storage temp. | Store at RT |
| solubility | DMSO: soluble40mg/mL |
| InChIKey | YBBLVLTVTVSKRW-UHFFFAOYSA-N |
| CAS DataBase Reference | 120511-73-1(CAS DataBase Reference) |
| Safety Information |
| Hazard Codes | Xi,Xn |
| Risk Statements | 36/37/38-22-61-60 |
| Safety Statements | 26-37/39 |
| RIDADR | 3249 |
| RTECS | CZ1465000 |
| HazardClass | 6.1(b) |
| PackingGroup | III |
| HS Code | 29339980 |
| Hazardous Substances Data | 120511-73-1(Hazardous Substances Data) |
| Anastrozole Usage And Synthesis |
| Indications and Usage |
Anastrozole is a potent selective triazole aromatase inhibitor that inhibits the aromatase that cytochrome P-450 is dependent on to prevent the biosynthesis of estrogen. Estrogen is the main stimulating factor for breast cancer cell growth. This drug’s half maximal inhibitory concentration (IC50) value to human placental aromatase is 15nmol/L. Compared to the traditional drug tamoxifen, Anastrozole can comprehensively and effectively lower the risks of breast cancer recurrence and metastasis, thus extending patients’ disease-free survival. Anastrozole is suitable for treating postmenopausal advanced breast cancer patients, especially postmenopausal advanced breast cancer patients who experienced recurrence following hormone assisted therapy. |
| Clinical Research | A series of clinical trials compared the effects of third generation aromatase inhibitor Anastrozole with those of tamoxifen. The trial was a global multicenter trial and includes 381 centers in 21 countries. Since 1996, there have been 9366 patients who have participated, and the follow-up time is 100 months. 25.8% of patients in the Anastrozole group experienced recurrence, while 29.9% of patients in the tamoxifen group did. Thus, Anastrozole’s recurrence rate was 4.1% lower than that of tamoxifen, and its risk of distant metastasis was lower as well. Anastrozole is also safer than tamoxifen. |
| Chemical Properties | Crystalline Solid |
| Uses | antiseptic, spermaticide |
| Uses | An aromatase inhibitor. Used as an antineoplastic. |
| Definition | ChEBI: A 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position. |
| Biological Activity | Potent and highly selective aromatase (CYP19) inhibitor (IC 50 = 15nM) that has no discernible effect on adrenocorticoid hormone synthesis. Reduces plasma estrogen levels and exhibits antitumor activity in vivo . Orally active. |